Leukemia Research Studies

< Back to Young Adult Cancer Research Studies Page

CML New Diagnosis

AAAML1921: Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

  • Ages: 1 Year to 18 Years

This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least on ...More

Contact Us

Contact us.

To learn more about available leukemia clinical trials, contact us at cancer@cchmc.org or 513-636-2799.